Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Adma Biologics Inc (NASDAQ: ADMA) closed at $17.26 in the last session, down -0.69% from day before closing price of $17.38. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 2.53 million shares were traded. ADMA stock price reached its highest trading level at $17.41 during the session, while it also had its lowest trading level at $17.105.
Ratios:
We take a closer look at ADMA’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 45.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 62.62. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 5.33. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5. Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 15 ’25 when Grossman Adam S sold 21,000 shares for $16.88 per share. The transaction valued at 354,480 led to the insider holds 2,031,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $391,860 on Jul 15 ’25. The President and CEO now owns 2,037,850 shares after completing the transaction at $18.66 per share. On Jul 15 ’25, another insider, Grossman Adam S, who serves as the Director and Officer of the company, bought 63,000 shares for $18.68 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4118771200 and an Enterprise Value of 4112306176. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.32, and their Forward P/E ratio for the next fiscal year is 19.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.67. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.69 while its Price-to-Book (P/B) ratio in mrq is 10.37. Its current Enterprise Value per Revenue stands at 8.673 whereas that against EBITDA is 25.144.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.53, which has changed by 0.041641474 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -2.78%, while the 200-Day Moving Average is calculated to be -7.89%.
Shares Statistics:
According to the various share statistics, ADMA traded on average about 3.05M shares per day over the past 3-months and 2374300 shares per day over the past 10 days. A total of 239.38M shares are outstanding, with a floating share count of 230.45M. Insiders hold about 3.43% of the company’s shares, while institutions hold 89.27% stake in the company. Shares short for ADMA as of 1755216000 were 14956909 with a Short Ratio of 4.91, compared to 1752537600 on 14470950. Therefore, it implies a Short% of Shares Outstanding of 14956909 and a Short% of Float of 7.7.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is $0.18, with high estimates of $0.18 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.59 and $0.54 for the fiscal current year, implying an average EPS of $0.56. EPS for the following year is $0.93, with 3.0 analysts recommending between $0.97 and $0.87.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $131.2M. It ranges from a high estimate of $133.3M to a low estimate of $130.1M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $119.84MFor the next quarter, 3 analysts are estimating revenue of $137.17M. There is a high estimate of $139.8M for the next quarter, whereas the lowest estimate is $133.5M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $509.61M, while the lowest revenue estimate was $503.5M, resulting in an average revenue estimate of $506.3M. In the same quarter a year ago, actual revenue was $426.45MBased on 4 analysts’ estimates, the company’s revenue will be $637.85M in the next fiscal year. The high estimate is $647.21M and the low estimate is $631M.
